疾病谱进展背景下脂肪性肝病诊断的重新审视

牛春燕; 刘勤; 罗晓春

doi:10.3969/j.issn.1001-5256.2020.10.043

疾病谱进展背景下脂肪性肝病诊断的重新审视

DOI: 10.3969/j.issn.1001-5256.2020.10.043

1. 南京市溧水区人民医院(东南大学附属中大医院溧水分院)消化内科
2. 西安医学院第一附属医院消化内科
3. 厦门大学医学院
4. 厦门大学附属翔安医院消化内镜中心

基金项目:

陕西省科技厅重点研发计划项目(2017SF-274)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 498
- HTML全文浏览量: 44
- PDF下载量: 79
- 被引次数: 0
出版历程
- 收稿日期: 2020-04-07
- 出版日期: 2020-10-20

Reexamination of the diagnosis of fatty liver disease under the background of disease spectrum progression

Department of Gastroenterology,Nanjing Lishui People's Hospital & Lishui Branch of Zhongda Hospital Affiliated to Southeast University
Department of Gastroenterology,The First Affiliated Hospital of Xi'an Medical University
Xiamen University Medical College
Center of Digestive Endoscopy,Xiang'an Hospital Affiliated to Xiamen University

Research funding:

摘要

摘要: 近年研究发现,代谢综合征[如肥胖、糖尿病、胰岛素抵抗、非酒精性脂肪性肝病(NAFLD)]与饮酒在许多个体中共存,提示酒精性肝病与NAFLD的重叠,以协同及相互作用的方式促进了脂肪性肝病的发生与进展,加重了脂肪性肝病的不良结局。脂肪性肝病的疾病谱演变对当前将脂肪性肝病分为酒精性肝病和NAFLD的排他性二分法诊断体系提出了挑战。归纳总结了近年来的相关研究进展,并介绍了最新发布的NAFLD更名国际共识意见,旨在建议关注饮酒与代谢综合征对NAFLD的影响,对脂肪性肝病的诊断提出见解,从而为对脂肪性肝病及其诊断和个体化治疗的重新审视提供新的依据。
- 脂肪肝 /
- 代谢综合征X /
- 饮酒 /
- 肥胖症
Abstract: Recent studies have shown that metabolic syndrome( MetS),e. g.,obesity,diabetes mellitus,insulin resistance,and nonalcoholic fatty liver disease( NAFLD),and drinking coexist in a considerable number of individuals,suggesting the overlap of alcoholic liver disease( ALD) and NAFLD promotes the development and progression of fatty liver disease and aggravates the adverse outcome of fatty liver disease in a synergistic and interactive way. The evolution of the disease spectrum of fatty liver disease challenges the exclusive diagnosis system which divides fatty liver disease into ALD and NAFLD. This article summarizes the research advances in recent years and introduce the latest international consensus on the renaming of NAFLD,aiming to pay attention to the influence of drinking and MetS on NAFLD,put forward our insights into the diagnosis of fatty liver disease,and thus provide a new basis for reexamination the diagnosis and individualized treatment of fatty liver disease.
- fatty liver /
- metabolic syndrome X /
- alcohol drinking /
- obesity

HTML全文

参考文献(38)

[1] ASRANI SK,DEVARBHAVI H,EATON J,et al. Burden of liver diseases in the world[J]. J Hepatol,2019,70(1):151-171.

[2] OECD. Obesity Update[EB/OL]. https://www. oecd. org/els/health-systems/Obesity-Update-2017. pdf. Accessed August 1,2019.

[3] LI J,ZOU B,YEO YH,et al. Prevalence,incidence,and outcome of non-alcoholic fatty liver disease in Asia,1999-2019:A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2019,4(5):389-398.

[4] World Health Organization. Global status report on alcohol and health 2018[EB/OL]. https://www. who. int/substance_abuse/publications/global_alcohol_report/gsr_2018. en/．Accessed August 1,2019.

[5] SHIELD KD,RYLETT M,REHM J. Public health successes and missed opportunities. Trends in alcohol consumption and attributable mortality in the WHO European Region,1990-2014(2016)[EB/OL]. http://www. euro. who. int/en/home.

[6] SINGAL AK,BATALLER R,AHN J,et al. ACG clinical guideline:Alcoholic liver disease[J]. Am J Gastroenterol,2018,113(2):175-194.

[7] CAO HX,FAN JG. Alcoholic fatty liver disease with nonalcoholic fatty liver disease and obesity[J]. J Clin Hepatol,2019,35(3):478-480.(in Chinese)曹海霞，范建高．酒精性肝病合并非酒精性脂肪性肝病和肥胖[J]．临床肝胆病杂志，2019,35(3):478-480.

[8] SINGH A,AMIN H,GARG R,et al. Increased prevalence of obesity and metabolic syndrome in patients with alcoholic fatty liver disease[J]. Dig Dis Sci,2020.[Online Ahead of Print]

[9] YAMADA K,MIZUKOSHI E,SEIKE T,et al. Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease[J]. PLo S One,2018,13(1):e0191026.

[10] BELLENTANI S,SACCOCCIO G,MASUTTI F,et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy[J]. Ann Intern Med,2000,132(2):112-117.

[11] FAZZINO TL,FLEMING K,SHER KJ,et al. Heavy drinking in young adulthood increases risk of transitioning to obesity[J].Am J Prev Med,2017,53(2):169-175.

[12] LOOMBA R,BETTENCOURT R,BARRETT-CONNOR E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults:The Rancho Bernardo Study[J]. Aliment Pharmacol Ther,2009,30(11-12):1137-1149.

[13]BERG F,HELENIUS-HIETALA J,PUUKKA P,et al. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population[J]. Hepatology,2018,67(6):2141-2149.

[14]BERG F,FRKKILM,MNNISTV. Interaction between alcohol use and metabolic risk factors for liver disease:A critical review of epidemiological studies[J]. Alcohol Clin Exp Res,2020,44(2):384-403.

[15] YOUNOSSI ZM,STEPANOVA M,ONG J,et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease[J]. Clin Gastroenterol Hepatol,2019,17(8):1625-1633. e1.

[16] DULY AM,ALANI B,HUANG EY,et al. Effect of multiple binge alcohol on diet-induced liver injury in a mouse model of obesity[J]. Nutr Diabetes,2015,5:e154.

[17]BERG F,PUUKKA P,SAHLMAN P,et al. Metabolic risk factors for severe liver disease among alcohol risk users in the general population[J]. J Hepatol,2019,70(Suppl):e273.

[18]BERG F,PUUKKA P,SALOMAA V,et al. Risks of light and moderate alcohol use in fatty liver disease:Follow-up of population cohorts[J]. Hepatology,2020,71(3):835-848.

[19] SAHLMAN P,NISSINEN M,PUUKKA P,et al. Genetic and lifestyle risk factors for advanced liver disease among men and women[J]. J Gastroenterol Hepatol,2020,35(2):291-298.

[20] BAECKER A,LIU X,LA VECCHIA C,et al. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors[J]. Eur J Cancer Prev,2018,27(3):205-212.

[21] FORD ES,GILES WH,DIETZ WH. Prevalence of the metabolic syndrome among US adults:Findings from the third National Health and Nutrition Examination Survey[J]. JAMA,2002,287(3):356-359.

[22] BOYLE M,MASSON S,ANSTEE QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome:Cofactors for progressive fatty liver disease[J]. J Hepatol,2018,68(2):251-267.

[23] LONGATO L,RIPP K,SETSHEDI M,et al. Insulin resistance,ceramide accumulation,and endoplasmic reticulum stress in human chronic alcohol-related liver disease[J]. Oxid Med Cell Longev,2012,2012:479348.

[24] NAVEAU S,GIRAUD V,BOROTTO E,et al. Excess weight risk factor for alcoholic liver disease[J]. Hepatology,1997,25(1):108-111.

[25] TESCHKE R. Alcoholic liver disease:Alcohol metabolism,cascade of molecular mechanisms,cellular targets,and clinical aspects[J]. Biomedicines,2018,6(4):106.

[26] MIYAKE T,KUMAGI T,HIROOKA M,et al. Low alcohol consumption increases the risk of impaired glucose tolerance in patients with non-alcoholic fatty liver disease[J]. J Gastroenterol,2016,51(11):1090-1100.

[27]BERG F,FRKKILM. Drinking and obesity:Alcoholic liver disease/nonalcoholic fatty liver disease interactions[J]. Semin Liver Dis,2020,40(2):154-162.

[28] MAHLI A,HELLERBRAND C. Alcohol and obesity:A dangerous association for fatty liver disease[J]. Dig Dis,2016,34Suppl 1:32-39.

[29] ALBILLOS A,GOTTARDI A,RESCIGNO M. The gut-liver axis in liver disease:Pathophysiological basis for therapy[J]. J Hepatol,2020,72(3):558-577.

[30] PARKER R,KIM SJ,GAO B. Alcohol,adipose tissue and liver disease:Mechanistic links and clinical considerations[J]. Nat Rev Gastroenterol Hepatol,2018,15(1):50-59.

[31] LOSURDO G,CASTELLANETA A,RENDINA M,et al. Systematic review with meta-analysis:De novo non-alcoholic fatty liver disease in liver-transplanted patients[J]. Aliment Pharmacol Ther,2018,47(6):704-714.

[32] KRAWCZYK M,LIEBE R,LAMMERT F,et al. Towards genetic prediction of non-alcoholic fatty liver disease trajectories:PNPLA3 and beyond[J]. Gastroenterology,2020,158(7):1865-1880.

[33] RAUSCH V,MUELLER S. Suppressed fat mobilization due to PNPLA3 rs738409-associated liver damage in heavy drinkers:The liver damage feedback hypothesis[J]. Adv Exp Med Biol,2018,1032:153-172.

[34] BIBBS,IANIRO G,DORE MP,et al. Gut microbiota as a driver of inflammation in nonalcoholic fatty liver disease[J].Mediators Inflamm,2018,2018:9321643.

[35] LITWINOWICZ K,CHOROSZY M,WASZCZUK E. Changes in the composition of the human intestinal microbiome in alcohol use disorder:A systematic review[J]. Am J Drug Alcohol Abuse,2020,46(1):4-12.

[36]BERG F,PUUKKA P,SALOMAA V,et al. Combined effects of alcohol and metabolic disorders in patients with chronic liver disease[J]. Clin Gastroenterol Hepatol,2020,18(4):995-997. e2.

[37] ESLAM M,NEWSOME PN,SARIN SK,et al. A new definition for metabolic dysfunction-associated fatty liver disease:An international expert consensus statement[J]. J Hepatol,2020,73(1):202-209.

[38] ESLAM M,SANYAL AJ,GEORGE J,et al. MAFLD:A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology,2020,158(7):1999-2014. e1.

施引文献

资源附件(0)

访问统计